Events

CERIS SSRI workshop on Innovation Procurement
JUL
Thu
06
09:30 - 19:30

This was 2 years ago

Location

Brussels

Renaissance Hotel
Rue de Parnasse 19, Brussels
Programmes
Security

Attachments

There is 1 attachment connected to this article.

Attachments are only accessible for people with an account on the NCP Flanders website.

Sign in (if you already have an account) or sign up.

The Community for European Research and Innovation for Security (CERIS) is organising a SSRI workshop on Innovation Procurement. The event will take place at Renaissance Brussels Hotel on 6 July 2023, and will focus on the potential procurement instruments and tools which reduce risk perception specifically related to public procurement in the domain of civil security.

Sessions include:

  • challenges and opportunities of pre-commercial procurement (PCP) - the supplier's perspective;
  • challenges and opportunities of PCP - the buyer's perspective;
  • complementary actions for more impactful innovation procurement;
    • joint cross-border public procurement
    • value engineering
    • functional specifications

Registration is mandatory. For more information, please visit the official website.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.